Monday, 12 October 2020

The Digital Present And The Organization Of Work: How COVID-19 Has Forced Pharma To Reorganize



This article looks at some of the ways through which pharmaceutical firms have adapted and will continue to adapt going forwards, considering digital technologies (such as those required for remote working) to the reorganization of the workforce. 
 
  • Protect employees 
  • Ensure products are safe 
  • Continue with as many operations as possible, in order to maintain profitability  
The 2020 COVID-19 pandemic changed the outlook on remote work for many pharmaceutical and healthcare organizations around the world. This chapter looks at the changes that have impacted on the workplace, including the shift towards remote working. With remote working comes new opportunities as well as security threats.
 
The article follows on from two other coronavirus related articles by the author for the IVT Network.

The reference is:


Sandle, T. (2020) The Digital Present And The Organization Of Work: How COVID-19 Has Forced Pharma To Reorganize, The Journal of Validation Technology, 26 (3): https://www.ivtnetwork.com/article/digital-present-and-organization-work-how-covid-19-has-forced-pharma-reorganize

For further details, please contact Tim Sandle.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Saturday, 10 October 2020

Pharmig virtual events


Pharmig want to leave this year on a virtual high note and have restructured the traditional face-to-face Annual Adriatic Conference (21st & 22nd Oct) and 28th Annual Conference (2nd & 3rd Dec) to now become ‘new normal’ virtual meetings.

Although the Adriatic event was researched with local contacts – you might well find the sessions are of interest to you too. Presentations include:


- Draft Annex 1 changes and its impact on cleaning & disinfection
- Impact of SARS-CoV-2 in cleanroom operations
- Biofilms in water
- Microbiological culture media

For the 28th Annual Conference sessions include:


- Megalab experience – testing for SARS-CoV-2 RNA from 0 to 3 million tests in 5 months
- Hand sanitizers: what to look for and how to test
- Conducting an effective remote audit
- Why wont my bugs grow?
 

And lots more...!

Do go to the website to view the agendas www.pharmig.org.uk

Take care and stay safe
#pharmig #microbiology #covid #audit #cleaninganddisinfection #culturemedia #mythsofpharmamicro #staysafe

 Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Thursday, 8 October 2020

Some countries showing spikes in COVID-19 transmission



 

Transmission of COVID19 in the Americas remains very active, with some countries suffering recurrent spikes in cases and the virus spreading in new and different ways, Pan American Health Organization (PAHO) Director Carissa F Etienne, said today.

“While Brazil and the U.S. remain significant drivers of new cases in our region, we’re concerned by spikes in cases – including in places that had effectively managed outbreaks, like Cuba and Jamaica. In fact, over the past 60 days, 11 countries and territories in the Caribbean have moved from moderate to intense transmission, which is a concerning development as countries reopen airspace,” she told a news briefing today.

Over 17 million cases of COVID-19 have been reported in the Americas, with more than 574,000 deaths, representing half of all cases worldwide and more than half of all deaths, Etienne noted.

The new ways in which it is spreading is among younger people who have mild or no symptoms and are unaware they are infected. In the US, young people, especially those aged 20-29 years old, represent 20% of new cases. “While many young people won’t become ill or require an ICU bed, they are not immune to developing the serious effects of COVID-19,” she said.

Elderly people and those with diabetes or hypertension are still vulnerable, “So I urge people of all ages to continue to wear masks, practice social distancing to protect themselves and avoid exposing others, the PAHO Director said.

Rates of severe COVID-19 have reduced

Dr. Etienne said, “that rates of severe COVID illness have fallen across our region. Today, fewer people are being hospitalized and fewer require intensive care than before, due in part to our growing knowledge of this virus and how to manage critically ill patients.“

PAHO has held more than 160 trainings, delivered more than 17 million COVID PCR tests, and millions more gloves, gowns and masks to keep health workers safe, she said, noting that “when hospitals are able to cope and manage patients, there are fewer deaths. These efforts have helped save thousands of lives and will continue to protect countless more.”

Etienne gave credit to the work of governments which “acted quickly to expand laboratory networks, increase hospital beds, and hire and train health care workers” As well as health care workers “for their dedication and commitment,” under difficult conditions.

Vulnerable groups at particular risk

Yet despite these efforts, Etienne highlighted that several groups remain at particular risk, particularly those “with limited access to prevention and care”, including black, Hispanic and Native American populations in the US which “are nearly three times as likely to contact COVID as their white counterparts.

Etienne also underscored the importance of addressing the health of indigenous populations and migrants in the Region of the Americas. “Migrant and refugee populations may be increasingly exposed and are at higher risk,” she said. “PAHO has provided support to national authorities in Ecuador, Costa Rica, Brazil and Mexico to design strategies so migrant populations can continue to have access to the food, health care and mental health support they need,” she said.

“Our solidarity towards migrants is not only key for controlling transmission and preventing unnecessary deaths due to COVID-19, but a core reflection of our shared belief that everyone has a right to health and we must leave no one behind,” PAHO’s director added.

Links

PAHO Director's Opening Remarks: https://www.paho.org/en/media/weekly-press-briefing-covid-19-situation-americas

 

Wednesday, 7 October 2020

Humidity levels could be key to coronavirus control



In terms of the climate, one research group maintain that as COVID-19 cases increase, understanding how climate affects the spread of the coronavirus is necessary. Aerosol of respiratory droplet transmission is well-known to be a primary vehicle for the rapid spread and continued circulation of viruses in humans. There is also strong support that environmental conditions will affect rates of virus transmission. With the SARS-CoV-2 virus, medical data has consistently detected the virus in the saliva of infected people. This is particularly so as winter virus infections are generally more common (and those of use based in the northern hemisphere) will experience cooler temperatures.

To this end, scientists have studied the impact of relative humidity, environmental temperature, and wind speed in relation to the human respiratory cloud and also with virus viability. 

 

 The key aspect from the research relates to a critical factor for the transmission of the infectious particles or virions (especially when they are immersed in respiratory clouds of saliva droplets).

This is the rate of evaporation. The importance of this is the way by which heat and mass transfer around and within respiratory droplets, affect the chance of infection, especially within a closed environment. The optimal conditions to reduce the chance of infection from coronavirus are environments with high temperature and low relative humidity. This is because such environs lead to high evaporation rates of saliva-contaminated droplets, and this is critical for reducing the virus viability.

The researchers call this factors the saliva liquid carrier-droplet evaporation rate. However, even under these optimal conditions the virus can still spread. This arises due to another factor: wind speed. This means the wind outdoors or air movement through air changes when indoors. Understanding the aerodynamics could influence social distancing guidelines. 


The significance of this research could be towards a better understanding of the evaporation and how this connects with climate effects. This could become the basis to a model that would enable scientists to better predict coronavirus concentration and hence to assess the viability of the virus or at least the potential for virus survival. Such a model could be possible through the use of a computational fluid dynamics platform. The researchers used a very specific model, called the three-dimensional multiphase Eulerian–Lagrangian computational fluid dynamics solver. This requires an understanding of the steady-state of heat and mass transfer in relation to flowing spherical particles, as viral particles 


Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

NHS needs support

 

Imagine waiting for months for the operation you or your loved one so desperately needs. Now imagine waking up this morning to the news that hundreds of thousands of us could face a “tsunami of cancelled operations” this winter. Knowing your wait for care could be dragged out even longer is a terrible feeling.

Without emergency funding, experts, NHS bosses and doctors are warning of a difficult winter ahead - with operations backing up, the usual winter chaos and a second wave of Covid-19 beginning to bite.

Right now, Chancellor Rishi Sunak is deciding where the government will spend money over the coming years. [4] And with so much at stake for all of us who rely on it, we have to make sure that funding our NHS this winter is right at the top of his agenda.

There are millions of us reading this email. And if all of us signed a petition today, it could be enough to pile on the pressure and secure the emergency funding our NHS so desperately needs. But we have to act fast - before Rishi Sunak makes his decisions.

If you think the Chancellor should do what it takes to protect our NHS this winter, please will you add your name? It takes 30 seconds to sign:

SIGN THE PETITION

Post (fromNHS United)

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Tuesday, 6 October 2020

COVID-19 and the immune system

 


Researchers from the US and China have found that COVID-19 can destroy T cells, a type of lymphocyte that plays a key role in the body’s immune system in a similar way to HIV, writes Annie Lennon.

T lymphocytes, also known as T cells, are key for identifying and eliminating pathogens in the body. They work by finding a cell infected by a pathogen, in this case the virus behind COVID-19, poking a hole in its membrane, and injecting it with toxic chemicals. These toxic chemicals then kill both the virus and the cell.

Now, a team of researchers from Shanghai and New York found that a unique structure in the virus’ spike protein fuses the virus and T cell together when they come into contact. This allows the virus to enter the T cell and essentially take over its behaviour, switching off its normal pathogen-fighting functions.

 

This finding comes after a clinical report released by the Chinese People’s Liberation Army’s Institute of Immunology in February stating that T cell number could significantly drop in patients with COVID-19. This was especially the case for those who were elderly or requiring intensive care treatment. They then correlated lower counts of T cells with a higher mortality risk.

See: https://www.labroots.com/trending/immunology/17341/covid-19-attack-immune-systems-hiv

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Monday, 5 October 2020

Putting disinfectant to the test: Designing a field trial



The final stage of disinfectant efficacy testing is the field trial. This is where the disinfectant(s) under qualification are studied during in-use conditions in facility cleanrooms. As disinfectants are used in rotation and they are affected by different factors, all variables need to be captured in the field trial. The challenge for many users is that the field trial has not been standardised (there is no European standard in existence, for example). Nevertheless, the importance of field trials is referenced as part of the hierarchy of European Standards (phase I basic screening [suspension] tests, phase II suspension and surface tests, phase III field trials) and in USP General Chapter of Disinfectants and Antiseptics <1072>. This reference means that conducting a disinfectant field trial is a regulatory expectation.

In relation to this, Tim Sandle has written an article:
Sandle, T. (2020) Putting disinfectant to the test: Designing a field trial, Cleanroom Technology, June 2020 at: https://www.cleanroomtechnology.com/news/article_page/Putting_disinfectant_to_the_test_Designing_a_field_trial/166799


The disinfectant field trial represents the final step in the disinfectant qualification process and it is the most important, as the exercise provides real-world data to support the efficacy of disinfection within the facility - something that is assessed within the user's cleanrooms, using locally determined techniques and frequencies, and as assessed against the typical microorganisms unique to the facility. This article has presented why the field trial is important and some of the key aspects to consider.

For further details, please contact Tim Sandle.

Posted by Dr. Tim Sandle, Pharmaceutical Microbiology Resources (http://www.pharmamicroresources.com/)

Special offers